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  Vitamin D is a secosteroid and its role in musculoskeletal health is known for almost a 
century. In the past two decades there have been a lot of research to explore the influence of 
vitamin D on skeletal and extraskeletal health and its action at molecular level. Vitamin D 
deficiency is pandemic(1) and vitamin D deficiency has been attributed to play a significant 
role in autoimmune diseases, malignancy, ischemic heart disease etc.   
 
   METABOLISM (Fig 1): 
             Cutaneous synthesis of cholecalciferol is the major source of vitamin D in humans. 
Vitamin D is obtained either from the diet (negligible in unfortified food) as vitamin D2 
(ergocalciferol) or as vitamin D3(cholecalciferol). Ergocalciferol is vitamin D2 obtained 
from plant source by the influence of ultraviolet B radiation, while cholecalciferol is vitamin 
D3 obtained from animal source or from the human skin by the influence of ultraviolet B 
radiation on 7-dehydrocholesterol(2). Once vitamin D is absorbed, it get bound to Vitamin 
D- binding protein, an alpha globulin , and is then taken up by the liver. The absorbed 
vitamin D is biologically inactive requiring transformation in liver and kidney to become the 
active form. In the liver, vitamin D is converted to 25 hydroxy vitamin D3(25OHD) by 25 
hydroxylase. This 25OHD is the predominant storage and circulating form of vitamin D.  In 
the kidney, it gets converted to 1,25 dihydroxy vitamin D3 by 1 alpha hydroxylase. 1,25 
dihydroxy vitamin D3 is the active form of vitamin D. The biologic effects of this active 
form is limited by 24 hydroxylase, which hydroxylates the active vitamin D3 into the 
inactive form.  The major inducer of 24 hydroxylase is 1,25 dihydroxy vitamin D3, which 
promotes its own inactivation.   
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Fig 1:Diagramatic representation of  Vitamin D metabolism.
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  Recent research over the past decade, shows that 1alpha hydroxylase, (mitochondrial 
CYP27B1 enzyme) is expressed in many extrarenal tissues like keratinocytes, hair follicles, 
epithelial cells, granulomas, parasympathetic ganglia, adrenal medulla, cerebellum, cerebral 
cortex, pancreas, placenta etc(3–5).  This enzyme converts 25OHD to active vitamin D 
which has  local autocrine and paracrine actions.  
 
MOLECULAR ACTION (Fig 2): 
    Vitamin D exerts its action predominatly by modulating  the gene expression. Vitamin D 
receptor(VDR) possess two zinc finger motifs and belongs to type II member of the nuclear 
hormone receptor superfamily(6).  Though VDR is present in most of the tissues, it is 
present in high concentration in kidney and small intestine. The VDR levels in target tissue 
is regulated by many factors like active vitamin D3, growth hormone etc. The steps involved 
in action of vitamin D is a) binding of 1α,25(OH)2D3 to the VDR in the cytosol, (b) 
hormone–receptor complex get translocated  to the nucleus, (c) binding of VDR–RXR 
heterodimers (RXR, retinoidX receptor) or VDR homodimersto the vitamin D response 
element (VDRE) to the promoter region of vitamin D-responding genes and (d) thereby 
enhancing gene expression and inducing target protein synthesis(6–10). 
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Fig 2: Molecular action of Vitamin D:1,25 dihydroxy vitamin D3 bind to Vitamin D 
receptor(VDR) and then complexes with Retinoid x receptor. This complex binds to 
Vitamin D response elements(VDRE) in the promoter region of the gene. The VDR/RXR 
complex combine with the coactivator proteins and induce transcription of the gene. 
 
 
 
 
 
 
 
6 
 
 
FUNCTIONS OF VITAMIN D: 
 
     The various musculoskeletal and extraskeletal actions of Vitamin D are numerous (as 
follows) which makes prevention and treatment of this vitamin (now considered as a 
hormone) of utmost importance. 
 
 
CALCIOTROPHIC ACTION: 
      
      Though the role of vitamin D and calcium on bone health is known for ages, there are 
various other functions influenced by calcium mediated neural transmission, exocrine 
secretion, muscle  activity, blood clotting, cell to cell interaction etc. Calcium homeostasis is 
a tightly controlled complex process that involves various hormones and factors.  The three 
important factors that influence calcium homeostasis are Parathyroid hormone(PTH), 1,25 
dihydroxy vitamin D and calcitonin(11).  PTH is secreted within few seconds of 
encountering hypocalcemia via cyclic-AMP mediated pathway. PTH acts on the kidneys via 
three mechanisms: (1) activates 1alpha hydroxylase in the proximal convoluted tubule, 
which converts 25OHD to active 1,25 hydroxy vitamin D, (2) inhibits 24-hydroxylase, 
thereby preventing inactivation of active vitamin D3, (3) prevents phosphate absorption in 
the renal tubules leading to phosphate diuresis.  Along with its action on osteoblasts, it 
increases serum calcium and favours phosphorous excretion(11). 
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       1,25-dihydroxy vitamin D3 induces absorption of calcium and phosphorous from the 
small intestine, and in the kidneys promotes absorption of filtered calcium. Heaney  et al(12) 
showed the differences in dietary calcium absorption with varying Se 25OHD levels, and 
concluded that to have optimum calcium absorption, Se 25OHD should be much higher than 
30ng/ml. Though vitamin D has no direct action on osteoclasts, it favours the formation of 
osteoclast precursors and stimulates osteoblasts to synthesize factors that favour the 
differentiation of osteoclasts. Osteoclasts favour bone remodelling by resorption, thereby 
shifting calcium from the bone to the plasma and maintaining calcium homeostasis. 
Calcitonin decreases mobilization of calcium from the skeletal tissue by directly acting on 
osteoblasts and osteoclasts(7,10).  
 
VITAMIN D AND HEALTH: 
 
RICKETS: 
    Rickets is disease of growing bones and most commonly occurs due to vitamin D 
deficiency. The growth plate thickness is determined by chondrocyte proliferation and 
vascular invasion.  The important factor that determine vascular invasion in the growth 
palate is mineralization of the cartilage.  This enhances the tensile strength of the growth 
plate. In vitamin D deficiency, there is defect in the mineralization of normal osteoid.  This 
leads to disorganisation of chondrocytes and poor mineralization of the growth plate 
(13,14). Defective mineralization results in thickening of the growth plate. Cupping and 
fraying of the metaphyses is secondary to decreased bone strength. The clinical features of 
rickets are delayed closure of fontanelles, parietal and frontal bossing, widening of the 
wrists, harrison sulcus, genu valgum, genu varus etc. Based on child‟s age and weight 
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bearing pattern, the deformity can vary. Posterior bowing of tibia and forearm deformities 
are commonly seen in infants, while genu varus is commonly seen in toddlers as they start 
to walk.  Windswept deformity (valgus deformity of one leg and varus deformity of the 
other) may be seen in older children. 
           Radiological  features of rickets are well appreciated  at sites where rapid bone 
growth occur. These changes are well appreciated  in the distal  ulna and metaphyses 
adjacent to the knees(15). Widening of the physeal plate and loss of the provisional zone of 
calcification at the epiphyseal - metaphyseal interface are the early signs of rickets . In later 
stages,  cupping, splaying,  fraying  and stippling may be seen. Other features are osteopenic 
long bones with thin cortices and delayed appearance of the epiphyseal centres. Spine 
changes include scoliosis, biconcave vertebral body, triradiate pelvis etc. Skull changes 
include basilar invagination, indistinct sutural margins, delayed tooth eruption etc. 
 
VITAMIN D AND EXTRASKELETAL EFFECTS: 
   The role of vitamin D in extraskeletal health has been extensively studied in the last two 
decades.  Finklea et al  showed that there is  a strong association of vitamin D deficiency 
with multiple pulmonary diseases like childhood asthma, cystic fibrosis, interstial lung 
disease, chronic obstructive pulmonary disease etc(16).  Vaidhya et al  showed that excess 
activity of renin-angiotensin system(RAS) plays a major role in the pathogenesis of 
hypertension, diabetes mellitus (insulin resistance and decreased insulin secretion) and renal 
diseases. He showed that vitamin D downregulates the expression of RAS, thereby exerting 
a major role in the prevention of these diseases(17). Yaturu et al also showed that vitamin D 
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deficiency is more prevalent in diabetic patients(18). In a study done by Moreno at al , he 
showed  vitamin D supplementation and regular sunlight exposure prevents type I DM(19). 
Al-Daghri et al showed improvement in metabolic syndrome with vitamin D 
supplementation(20). 
 
 Vitamin D plays a significant role in the innate and adaptive immunity through various 
mechanisms. Korf H et al showed vitamin D regulated the inflammatory and T cell 
stimulatory function of macrophages through IL-10 mediated mechanisms(21). Campbell et 
al showed that vitamin D mediated-autophagy plays a significant role in prevention of HIV 
infection(22). Grey et al showed the association of vitamin D deficiency with pulmonary 
tuberculosis(23).  
  Vitamin D modulates cellular proliferation and differentiation. Thus vitamin D deficiency  
plays a significant role in various malignancies like breast cancer(24), colon cancer(25), 
prostate cancer(26), cutaneous malignancies(27) etc.  
  Hence, considering the magnitude of functional importance of Vitamin D, it is becoming 
more and more important to treat as well as prevent this deficiencny. There is still an 
ongoing controversy regarding the various aspects of this vitamin even including the desired 
optimal levels. There are some guidelines regarding supplementation of vitamin D in adults, 
and very few in children. Even in this the various „authorities‟ have differed in their 
supplementation doses. There are some guidelines on treatment of rickets (symptomatic 
vitamin D deficiency). Seeing this growing importance of Vitamin D in prevention of a host 
of other musculoskeletal and extraskeletal functions; it is probably important to prevent this 
10 
 
deficiency. Literature on requirement/supplementation of vitamin D in asymptomatic 
children is scarce. Vitamin D supplementation have been done via supplementing Vitamin 
D2 or D3, oral or intramuscular, daily or stoss therapy,  Still there does not exist any 
standard non-controversial guidelines for Vit D supplementation.. Hence this study was an 
attempt to see the effect of three different doses of  cholecalciferol supplementation 
protocols in children with asymptomatic vitamin D deficiency. 
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                 AIMS AND OBJECTIVES 
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To analyze the effect of vitamin D (cholecalciferol) supplementation on serum 25OHD level in 
asymptomatic Vitamin D deficient children:  Comparison of three different vitamin D 
supplementation protocols. 
 
 
i.   Primary Outcome:   
a. To compare the efficacy of three different vitamin D supplementation 
protocols in raising Se 25OHD levels. 
 
ii. Secondary Outcomes:    
a. To analyse the side effects of cholecalciferol  supplementation, if any, in 
children. 
b. To see whether Body Mass Index (BMI) has any effect on change in serum 
25OHD levels after supplementation with cholecalciferol.  
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                            LITERATURE REVIEW 
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         Dr. Daniel Whistler and Professor Francis Glisson were the first to scientifically 
describe rickets in 17
th
 century, although Hippocratus has described bony disease similar to 
rickets as early as 130 AD. In 18
th
 century, cod liver oil was used to treat rickets and further 
research showed some vital substance in the cod liver oil responsible for the curative effect. 
Several research were done in 18
th
 and 19
th
 century, showed that diet has certain important 
factors especially in fat, which is required for bone growth. 7-dehydrocholesterol, the 
precursor of vitamin D was first described by Goldblatt and Soames in 1923, and proved 
that when this precursor is irradiated by sunlight, an active fat soluble vitamin is produced 
which helps in curing rickets. Similarly, Hess and Steenbock in 1924 named the substance 
in the skin activated by sunlight as “provitamin D”. The native vitamin D was first isolated 
by Professor A. Windaus in 1930, for which he received the Noble prize. Since then, there 
continues to be a lot of research being done worldwide to explore further metabolism of 
vitamin D, its action at molecular level and its role in diseases other than rickets.  
 
SOURCES OF VITAMIN D: 
   Sunlight is the predominant source of Vitamin D. The cutaneous synthesis of Se 25OHD 
from 7 –dehydrocholesterol (by the effect of ultraviolet rays on the skin) depends on a lot of 
factors like latitude, skin complexion, age, pollution, sun screen, skin disorders, etc.  When 
arms and legs are exposed to sunlight for 10 to 15 minutes (in western population) the 
amount of  vitamin D synthesized  varies between 3,000 to 20,000 units(28).  Haddad et al 
(29) showed that  the half life of vitamin D synthesized from the skin is longer than the 
ingested vitamin D.   
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The availability of vitamin D from unfortified food is negligible and very few. The food 
sources rich in vitamin D are cod liver oil(8000 – 30,000 units/100g), shark liver oil(4000 
units/100g), liver and some fish(200-1200 units/100g). Availability of fortified foods in the 
developing countries are rare and as opposed to that of Western countries. Centre for 
Disease Control and Prevention(CDC) recommends regular supplementation of all breast 
fed infants because the amount of vitamin D in human milk is very less (approximately 25 
units per litre)(30).  
 
DIETARY REFERENCE INTAKE: 
   The Dietary Reference Intake (DRI) of vitamin D and calcium as recommended by The 
Food and Nutritional Board, the Institute of Medicine (The National Academy of Sciences) 
in 2011 has been summarized in the tables 1 and 2.   The DRI is a common term to represent 
various reference values like Recommended Dietary Allowance(RDA), Adequate 
Intake(AI), Estimated Average Requirement(EAR) and Tolerable Upper Intake level(UL). 
 RDA: Average daily intake sufficient to meet the requirements of nearly all  healthy people. 
AI: Level assumed to ensure adequacy of the nutrition, when evidence is not enough to 
develop RDA. 
UL: Maximum daily intake unlikely to cause adverse health effects. 
EAR: Level required to meet the need of 50% of the healthy people . 
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Table 1:DIETARY REFERENCE INTAKE(DRI)  FOR VITAMIN D (IU/day)*: 
        AGE             AI              EAR         RDA 
     0-6 months 
    6-12 months 
      1-3 yrs 
     4-8yrs 
     9-13yrs    
    14-18yrs                   
         400 IU 
         400 IU 
            _ 
            _ 
            _ 
           _ 
             _ 
             _ 
            400 IU 
           400 IU 
           400 IU 
           400 IU 
            _ 
            _ 
          600 IU 
          600 IU 
          600 IU 
          600 IU       
 RDA = Recommended Dietary Allowance  .AI = Adequate Intake;    IU = International 
Unit;          EAR = Estimated Average Requirement;  
*Dietary Reference Intakes for Calcium and Vitamin D (2011),  Food and nutrition board, 
Institute Of medicine, THE NATIONAL ACADEMY OF PRESS. 
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Table 2:DIETARY REFERENCE INTAKE(DRI)  FOR CALCIUM (mg/day)*: 
        AGE             AI              EAR         RDA 
     0-6 months 
    6-12 months 
      1-3 yrs 
     4-8yrs 
     9-13yrs    
    14-18yrs                   
         200mg 
         260mg 
            _ 
            _ 
            _ 
           _ 
             _ 
             _ 
            500mg 
           800mg 
           1100mg 
           1100mg 
            _ 
            _ 
          700mg 
          1000mg 
          1300mg 
          1300mg       
RDA = Recommended Dietary Allowance . AI = Adequate Intake;   IU = International Unit;            
EAR = Estimated Average Requirement;  
*Dietary Reference Intakes for Calcium and Vitamin D (2011),  Food and nutrition board, 
Institute Of medicine, THE NATIONAL ACADEMY OF PRESS. 
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FACTORS DETERMINING VITAMIN D STATUS: 
      In humans, 90% of vitamin D requirement is met through cutaneous synthesis and the 
rest from the diet(31).  Even though India is a sunny country throughout the year, there is a 
high prevalence of vitamin D deficiency, the reasons being primarily cultural and lifestyle 
related, inappropriate timing and  lesser duration of sunlight exposure, pollution, less 
amount of body surface area exposed, skin pigmentation, sunscreen, and genetic factors(31). 
To maintain optimum cutaneous synthesis of vitamin D, 40% of the body surface area 
should be exposed to the sunlight between 10 A.M and 3P.M, when there is predominant 
UVB radiation(32).   
 
     Al Attia et al(33) showed that the dressing patterns significantly influence the vitamin D 
status. Matsuoka et al(34) showed that black wool clothes significantly attenuate UVB 
radiation compared to cotton clothes, thereby decreasing the cutaneous production of 
vitamin D.  Norman et al(35) showed that cutaneous melanin is a natural sunscreen, which 
interferes  with the peneteration of UVB rays into stratum basale where 7-
dehydrocholesterol is abundant.  Hollick et al(36) showed that Asian children require three 
times more the sun exposure compared to light skinned person.  
 
    The influence of seasonal variation on vitamin D status is a well known fact especially in 
the western population. Studies done by Guessous et al(37) and Janssen et al(38)  showed 
vitamin D deficiency is more prevalent in winter season. In tropical countries, which 
remains sunny throughout the year, this association remains controversial.  Kim SH et al 
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showed that vitamin D deficiency is more prevelant in Korean adolescents during winter 
season(39), similary Lu HK et al also showed vitamin D deficiency is more prevalent during 
winter season in Chinese population(40). We recruited the participants by block 
randomization to avoid the bias due to seasonal variation. 
 
    Sunscreen with sun protection factor(SPF) of 8 decreases cutaneous production of 
vitamin D by 95% and sunscreen with SPF of 15 decreases cutaneous synthesis by 98%(41). 
Hollick et al(42) showed that vitamin D deficiency is more prevalent above 37 degrees 
latitude  especially in winter months because of decrease in the amount of  UVB radiation.  
Agarwal et al(43) and Humayun et al(44) showed that vitamin D deficiency is more 
common in people living in areas of high atmospheric pollution. 
       
 Robein et al(45) showed that genetic polymorphism of enzymes involved in vitamin D 
metabolism(cytochrome P2R1 and cytochrome P3A4) and vitamin D binding protein have 
significant influence on vitamin D status. 
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CAUSES OF VITAMIN D DEFICIECNY: 
1.DECREASED VITAMIN D SYNTHESIS:  
            A. Skin pigmentation 
            B. Physical agents blocking UVB exposure:  clothing, shade, sunscreen, and chronic 
eczema. 
           C.Geography: Altitude, Latitude, season and atmospheric pollution 
2.DECREASED NUTRITIONAL INTAKE OF VITAMIN D 
3.FACTORS INTERFERING WITH VITAMIN D ABSORPTION/METABOLISM: 
           A. Malabsorption syndromes. 
           B. Chronic liver disease 
           C. Chronic renal disease 
           D. Drugs: Steroids, antiepileptic agents, antituberculous therapy etc. 
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VITAMIN D DEFICIENCY: 
         The criteria to define vitamin D deficiency has been changed from time to time. 
Institute of Medicine defined vitamin D deficiency as Se 25OHD less than 11ng/ml way 
back in 1997 (46), Since then it has been revised multiple times. Misra et al (31) considered 
Se 25OHD level below 15ng/ml as vitamin D deficiency and level between 15-20ng/ml as 
vitamin D insufficiency. The most widely accepted definition for vitamin D deficiency is 
Se.25OHD less than 20ng/ml(2,47,48).   Craig et al(49) classified vitamin D deficiency into 
mild, moderate and severe based on se 25 OHD level(Table 3)  
 
Table 3:Calssification of vitamin D deficiency based on Se 25OHD levels: 
                 VITAMIN D STATUS                Se 25OHD level 
       Mild Vitamin D deficiency 
     Moderate Vitamin D deficiency 
     Severe Vitamin D deficiency 
             10-20 ng/ml (25-50nmol/L) 
            5-10 ng/ml (12.5-25nmol/L) 
            <5 ng/ml (<12.5nmol/L) 
 
          
        Clienferotti et al(50), Haroon et al(51) and Holick et al (47)  have shown in their 
studies  that to have good musculoskeletal and extraskeletal health, Se 25OHD should be 
maintained more than 30ng/ml.  Current IOM as well as Endocrine Society of Clinical 
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Practice Guideline consider Se 25OHD level between 21-29ng/ml as Vitamin D 
insufficiency and <20 ng/ml as deficiency (47).  
     
PREVALENCE 
The prevalence of vitamin D deficiency vary from place to place. In a study done by 
Buyukinan et al(52) in 106 Turkey children, he found that 62% were vitamin D deficient 
and 34% were vitamin D insufficient. He also documented that vitamin D deficiency is 
more common in pubertal age group and there is strong correlation of insulin resistance with 
vitamin D deficiency. 
       Santos et al(53), studied the prevalence of vitamin D deficiency and genetic 
polymorphism of vitamin D receptor in girls living in South Brazil. Among 234 girls 36.3%  
had vitamin D deficiency and 54.3% had vitamin D insufficiency. He also found that VDR 
gene polymorphism(Apal, TaqI and BsmI variants of VDR gene) is associated with vitamin 
D deficiency. 
    Gordon et al(54) have done a cross sectional study to find the prevalence of vitamin D 
deficiency in infants and toddlers (population =365) and found that 12.1%  had vitamin D 
deficiency and 40% had vitamin D insufficiency. Uush et al(55) have done a study in 
Mongolian children and found that 21.8% had vitamin D deficiency and 20% had vitamin D 
insufficiency.  
     Camargo et al(56) studied vitamin D status of newborns in New Zealand, by analyzing 
cord blood  Se 25OHD. Among 929 newborns, only 27% had Se 25OHD more than 
30ng/ml,  57% had vitamin D deficiency, and 19% had Se 25OHD less than 10ng/ml. Al-
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Othman et al(57) studied vitamin D status in 331 Saudi children and found that all the 
participants were vitamin D deficient.  
        Even the sunny Indian subcontinent is not spared, with all parts of the country 
documenting a high prevalence of vitamin D deficiency. Puri et al(58) studied the vitamin D 
status in  3,127 school girls from different socioeconomic strata in Delhi and found that only 
11.5% had clinical vitamin D deficiency but asymptomatic (biochemical) hypovitaminosis 
D was seen in more than 90% (91.9% in upper socioeconomic group and 89.6% in lower 
socioeconomic group). of the study population. 
       Marwaha et al(59) studied vitamin D status in 5137 north Indian children and found that 
85% of children in upper socioeconomic group had vitamin D deficiency, 92.6% of children 
in lower socioeconomic group had vitamin D deficiency and 10.8% had clinical evidence of 
vitamin D deficiency.  
    Harinarayanan et al(60) studied vitamin D status in Southern India (on adults) and 
showed that vitamin D deficiency is more prevalent in urban population compared to rural 
population.  In rural population, vitamin D deficiency was observed in 44% men and 70% 
women compared to urban population where 62% men and 75% women had vitamin D 
deficiency.  
            Mithal et al(1)  analyzed vitamin D status of six regions of the world( Asia, North 
America, Latin America, Europe, Middle East and Africa and Oceania) by reviewing  
published literature. He found that vitamin D deficiency is pandemic and more prevalent in 
South Asian population. The reason being increased skin pigmentation and clothing. He also 
showed that older age and female sex were individual risk factors for vitamin D deficiency. 
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But in South Asian countries vitamin D deficiency was equally prevalent in all age groups. 
The seasonal variation, cultural factors and latitude also influence vitamin D status.  
 
 
PHARMACOLOGICAL PREPARATIONS AVAILABLE  IN INDIA      
          In India, vitamin D is available mainly as cholecalciferol sachets (60,000 
units/sachet), {tablets of 1000 units cholecalciferol (rarely)} and in combination with 
calcium containing tablets (usually 250U or 500 U/tablet). There are various treatment/daily 
maintenance doses proposed for the treatment of hypovitaminosis D. The therapy proposed 
in western population prescribe cholecalciferol in doses of 400 units, 600 units, 1000 units 
etc(48). In India, vitamin D is not available in such small doses, so most of the pediatricians 
prefer to use cholecalciferol sachet and divide the granules into equal parts based on the 
dose required. The cholecalciferol granules are heat and light sensitive, and hence should 
not be re-used if once the sachets are opened. 
 
VITAMIN D PHARMACOKINETICS: 
           The half life of  Se 25OHD is 3-4 weeks. Soliman et al(61) studied the effectiveness 
of intramuscular injection of mega dose of cholecalciferol in treating rickets. He showed 
that IM injection has slow and sustained response compared to oral therapy where the 
response is rapid but last for shorter duration.  Zabihiyeganeh et al (66) conducted 
randomized interventional study comparing oral with intramuscular vitamin D therapy.  
They showed that oral therapy has a better effect in raising the Se 25OHD compared to IM 
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therapy at three months of therapy, but there is no difference between the groups after 6 
months.  
          Ergocalciferol is the plant source for vitamin  D, while cholecalciferol is the animal 
source for vitamin D. Ergocalciferol is metabolized quickly compared to cholecalciferol. 
Armas et al(62) compared the effectiveness of vitamin D2 with  Vitamin D3 and found that 
the initial response was similar in both the groups, but Se 25OHD tend to fall after third day 
in Vitamin D2 group and reach the baseline by day 14.  Logan et al(63) showed that long 
term cholecalciferol therapy is more effective than ergocalciferol therapy in maintaining 
steady state of Se 25OHD. Endocrine Society Clinical Practice Guideline (47) recommends 
that either vitamin D2 or Vitamin D3 can be used to treat hypovitaminosis D, but the 
treatment should be followed by maintenance therapy.  In India, Vitamin D2 is not 
available. In our study, we used vitamin D3 for the treatment and compared daily therapy 
with weekly therapy. 
   
DOSING SIZE AND SCHEDULE 
      There are very few studies in children with oral daily doses of vitamin D 
supplementation for asymptomatic vitamin D deficient children. We mention the few 
relevant studies. Majority have been stoss therapies for treatment of rickets. 
      Catherine et al(48) compared the efficacy and safety of three regimens in treating 
vitamin D deficiency in infants and toddlers. She screened 380 infants and toddlers and 
recruited 40 childrens. Twelve children received 2000 units of ergocalciferol(Vitamin D2) 
daily, fourteen children  received 50,000 units of ergocalciferol(Vitamin D2) weekly and 
fourteen(Vitamin D3) received 2000 units cholecalciferol daily. Treatment was given for 6 
26 
 
weeks. Participants were analysed one week after completion of treatment. They used one 
way ANOVA for continuous measures and Fisher‟s test for dichotomous variables. All the 
treatment regimens increased the vitamin D level by three fold . The effect difference 
compared between between daily Vitamin D2 and weekly Vitamin D2 was 12% but it was 
insignificant (p=0.66). Similarly the effect difference compared between daily Vitamin D2 
and daily Vitamin D3 was 7% which was also insignificant(p=0.8). The mean change in Se 
calcium level was minimal and similar in all the groups. At recruitment , 8 participants had 
elevated PTH level and it returned to normal after treatment. The greatest response was seen 
in participants who received Vitamin D2 weekly compared to othe two groups. But it is not 
statistically significant(p=0.74). There was no evidence of hypervitaminosis D in this study. 
But the main limitation in this study is the small sample size. 
      Endocrine Society Clinical Practice Guideline(47), recommends 2000 units of 
ergocalciferol or cholecalciferol daily or 50,000 units of ergocalciferol or cholecalciferol 
weekly once for 6 weeks to treat vitamin D deficiency in infants. The dosage is sufficient 
enough to raise the Se 25OHD above 30ng/ml.. After 6 weeks all the patients should be 
started on maintenance vitamin D (i.e) 400-1000 units / day of vitamin D. The vitamin D 
toxicity is unlikely with these regimens. Endocrine Society Clinical Practice 
recommnends(47) 2000 units of ergocalcifreol or cholecalciferol daily or 50,000 units of 
ergocalciferol or cholecalciferol weekly once for 6 weeks to treat vitamin  deficiency in 
children aged 1 to 18 yr. To maintain Se 25OHD level above 30ng/ml, the treatment should 
be followed by maintenance vitamin D theapy(600-1000 units of vitamin D/day) 
     Australia and New Zealand guidelines 2006 by Craig et al(49) reviewed the literature 
regarding vitamin D status in children and prepared consensus guidelines on treating infant 
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and children with hypovitaminosis D in New Zealand and Australia.   They suggest vitamin 
D should be supplemented to all breast fed infants till 12 months of age to prevent 
hypovitaminosis D. They recommend 400 units of vitamin D daily as vitamin D prophylaxis 
for children. If compliance is an issue, they advise 1.5 lakh units of vitamin D yearly once. 
Either ergocalciferol or cholecalciferol was advocated for treatment of hypovitaminosis D.  
The treatment for vitamin D deficiency was 1000 units/day for neonates, 3000 units/day for 
infants and 5000 units/day for children more than 1yr of age for a period of 3 months 
followed by maintenance vitamin D supplementation. 
   Shah et al(64) used of oral stoss therapy (3 lakh/6lakh units of vitamin D2 or vitamin D3 
as single or three to four divided doses) for treating hypovitaminosis D and found that there 
is significant improvement in Se 25 OHD levels but the risk of hypervitaminosis do exist, 
especially in younger children.   
    Cesur et al (65) compared three different treatment regimens for treating nutritional 
vitamin D deficiency in children less than 3 years. The three treatment regimens are single 
dose of 1.5 lakh units, single dose of 3 lakh units and single dose of 6 lakh units. Out of 56 
patients , 52 were followed up.  There was significant improvement in vitamin D status in 
all the participants irrespective of the groups. But six children who received single dose of 6 
lakh units and 2 children who received single dose of 3 lakh units developed hypercalcemia. 
.  
       Soliman et al(61) studied the effectiveness of intramuscular injection of mega dose of 
cholecalciferol in treating rickets. He treated 40 children with rickets with single dose of IM 
cholecalicferol(10,000 units/kg) and evaluated the cllnical, biochemical and radiological 
response over  3 months. At recruitment, the frequent manifestations were cranial bossing, 
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hypotonia, wide open anterior fontanel, enlarged wrist joint, harrison‟s sulcus and delayed 
dentition. The most common biochemical abnormality other than low Se 25OHD was 
elevated Se alkaline phosphatase(100%), low Se phosphorous(75%) and then low Se 
calcium(12.5%). Se Calcium, Se Phosphorous and Se 25OHD normalized after 1 month , 
while Se alkaline phosphates and Se PTH normalised after 3 months. After 3 months of IM 
injection, 12.5% had Se 25OHD <20ng/ml and 87.5% had Se 25OHD >20ng/ml. 
Hypercalcemia was not observed in any participant. Clinically significant improvement in 
rickets was noticed in all the participants. Radiologically 95% of children showed complete 
healing of rickets. This study shows IM vitamin D therapy has slow and sustained response 
compared to oral therapy which has rapid response but the response last only for short 
duration. 
      Zabihiyeganeh et al (66) conducted  a randomized interventional study comparing oral 
with intramuscular vitamin D therapy. He recruited 92 patients and randomized them into 
two groups. One group received single dose of 3 lakh units of cholecalciferol  IM and the 
other group received 3 lakh units cholecalciferol oral in six divided doses over a period of 
three months. There was significant improvement in the Se 25OHD in both the groups. The 
delta change of Se 25OHD at 3 months was higher with oral therapy (90 ± 11nmol/L) 
compared to IM injection group (58.8 ± 8.9nmol/L) which is statistically significant 
(p=0.03). But the delta change of Se 25OHD in oral therapy group(52± 7.6nmol/L) and 
injection group (62.2±6.7nmol/L) was similar(p=0.3) after 6 months. 
     Markestad et al (67) studied the effectiveness of intermittent high dose ergocalciferol 
prophylaxis in infants. Forty three infants were recruited and 6,00,000 units of 
ergocalciferol was given at one month of age, 4 months, 11 months, 15 months and 20 
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months. Se 25OHD and other biochemical parameters were measured two weeks before and 
two weeks after supplementation.  Se 25OHD levels significantly increased within 2 weeks 
but values returned to normal before the next dose (p<0.001).  After the first dose, 1,25 
dihydroxy vitamin D3 increased in all the infants(p<0.005), but there was no consistent 
pattern following subsequent doses. Fourteen infants developed hypercalcemia during the 
course of the study. There is no evidence of cumulative increase in Se 25OHD levels even 
after high dose intermittent therapy. 
   Carnes et al(68) compared the effectiveness of two treatment protocols in treating 
adolescents with vitamin D deficiency.  In his study, 22 healthy adolescents  with  Se 
25OHD were recruited. One group received oral 3,00,000 units 6 monthly,  other group oral 
1,50,000 units 6 monthly  with contol group which received placebo for 1year. After 12 
months, the mean Se 25OHD in the group which received 3,00,000 units was 63nmol/L, in 
the group which received 1,50,000 units it was 41.1nmol/L and was  35.8nmol/L in the 
placebo group. The difference between the group that received high dose compared to the 
placebo group was significant(p=0.004). There were no complications observed in any 
participant. This study shows 3,00,000 units once in every six months can be used  in 
treating adolescents with vitamin D deficiency.  
  
       Emel at al(69) compared the effectiveness of low dose stoss therapy with high dose 
daily vitamin D therapy in treating children with vitamin D deficiency. Forty two  children 
less than three years with Se 25OHD level <20ng/ml were recruited. Twenty one children  
received  low doss stoss therapy (i.e) 1,50,000 units oral cholecalciferol single dose and 
twenty one children received 2000 units cholecalciferol once daily for 6 weeks. Both the 
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groups showed significant response in Se 25OHD. Children who received low dose stoss 
therapy showed better response compared to group that received daily therapy(p<0.001). 
There was no evidence of hypervitaminosis in any participant.     
      Studies have shown that dietary deficiency of calcium alone can lead to rickets(70). 
Aggarwal et al(71) conducted a randomized interventional study to compare the 
effectiveness of  three different  treatment regimens in healing rickets in children. Sixty 
seven children with rickets were recruited and randomized into three groups. One group 
received 6 lakh units IM cholecalciferol, second group received only calcium(75mg/kg/day ) 
and the third group received both cholecalciferol and calcium for 12 weeks. At 12 weeks 
biochemical and radiological evidence of healing were evident in all the participants. After 
treatment, complete biochemical and radiological healing are seen in 50% of children who 
received combined therapy,  15.7% of children who received vitamin D alsone, and 11.7%  
in group which received calcium alone. This shows combined vitamin D and calcium  
therapy is more effective in treating rickets. 
 
EFFECT OF BMI : 
    Vitamin D influences the normal metabolic function of adipose tissue. Vitamin D inhibits 
the transcription factors in the adipocytes and thereby prevent the accumulation of lipid 
during adipocyte differentiation(72). Vasilopoulos et al(73) studied the association between 
Vitamin D receptor polymorphism and obesity. They showed that polymorphism in VDR 
TaqI gene is associated with increased risk of obesity. Josefson et al(74) studied the 
association between maternal obesity and vitamin D status in the newborn. They showed 
that Se 25OHD transferred to the fetus from the obese mother is comparatively lesser than 
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normal weight mother,despite similar serum levels. Though studies have shown that BMI 
has significant influence on treatment response(76), there is paucity of literature regarding 
whether dosing should be based on BMI, weight or severity of vitamin D deficiency.  
 
SIDE EFFECTS OF VITAMIN D SUPPLEMENTATION 
Hypervitaminosis D is defined as Se 25OHD more than 150ng/ml(76), but vitamin D 
toxicity has been observed when Se 25OHD more than 300ng/ml(750nmol/L) (75). 
Hypervitaminosis D  is not an uncommon phenomenon observed with treatment for vitamin 
D deficiency. Probable reasons could be 1) because most of the treatment  regimens 
recommend uniform dosing irrespective of age or weight., 2) dosing is probably given 
without monitoring and  3) misuse. Whether age or weight is a determinant for vitamin D 
dosing is not known and in our study we have taken a lower dose for smaller weight 
children to avoid Vit D toxicity. 
    
     The clinical features of hypervitaminosis D are headache, pruritis, vomiting, 
hypercalcemia, hypercalciuria, hematuria etc. Hollick et al(77) showed hypervitaminosis 
occurs when the daily dosing exceeds 10,000 units . Ceuser et al(78) showed vitamin D 
toxicity occurs when single oral dose exceeds 3 lakh units. 
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STUDY DESIGN: 
     Randomized parallel group interventional trial. 
 
STUDY PERIOD: 
    A period of 12 months from December 2011 to November 2012. 
 
STUDY SUBJECTS 
Inclusion Criteria 
 Children aged 1 year to 18 years presenting to the Paediatric Outpatient Department of 
Christian Medical College, Vellore with serum 25OHD level < 20ng/ml and  residing within 
300 km of Vellore. 
Exclusion Criteria: 
     1. Children with symptomatic vitamin D deficiency (including skeletal manifestations of 
rickets) 
     2. Serum Calcium < 8.0 mg/dl. 
     3. Children already receiving calcium and vitamin D supplements. 
     4. Presence of conditions that can interfere with vitamin D absorption and metabolism. 
i.  Malabsorption syndromes, liver disease and renal disease 
ii. Drugs like antituberculous therapy, antiepileptic agents and steroids. 
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SUBJECTS 
    Children residing within 300km in and around Vellore (Latitude 12° 55' N)  and with 
vitamin D deficiency (Se 25OHD level less than 20ng/ml) were evaluated for features of 
vitamin D deficiency like hypocalcemia (Se Calcium< 8mg/dl), clinical features of rickets, 
and for any other secondary causes that interfere with vitamin D absorption and metabolism 
like malabsorption syndrome, renal disease, liver disease and drugs like antituberculous 
therapy, antiepileptics etc. Children with features of vitamin D deficiency, or with 
secondary causes that could interfere with vitamin D absorption and metabolism and those 
already on vitamin D and calcium were excluded from our study.    
     We discussed with the participating children (wherever applicable) and their 
parents/guardians regarding the study protocol, and recruited them after getting written 
informed consent. Once the child was recruited, he/she was randomized by block 
randomization and allocation was done through opaque envelopes which were serially 
allocated to participants.  They were randomized into three groups 
GROUP A: received  6000 units of vitamin D3 daily oral  
GROUP B: received 10,000 units of vitamin D3 daily oral 
GROUP C: received 60,000 units of vitamin D3 weekly once oral 
All the groups received the supplementation for a total period of 6 weeks.   
     Children who weighed less than 15 kg received half the dose of cholecalciferol than their 
respective counterparts (i.e., Group A-6000 units alternate day, Group B-10,000 units 
alternate day and Group C- 30,000 units once weekly).  
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RANDOMIZATION: PERMUTATED BLOCK RANDOMIZATION 
      Participants in the three treatment groups were arranged into six blocks by permutation 
and combination. The six blocks were arranged based on randomly assigned numbers. 
Participants were recruited uniformly throughout the year. 
The three treatment groups were: 
A- 6000 units of oral cholecalciferol/day  
B- 10,000 units of oral cholecalciferol/day 
C- 60,000 units of oral cholecalciferol/week 
  If the participant weighed less than 15 kg, we used half the dose compared to their 
counterparts in each group(i.e) Group A-6000 units alternate day, Group B-10,000 units 
alternate day and Group C-30,000 units weekly once for 6 weeks 
 
ALLOCATION CONCEALMENT:   
    Pre-numbered identical opaque covers; which were administered serially to the 
participants. 
 
 
         Each participant was given oral cholecalciferol (Calcirol granules, Torflash 
Md.Torrent) without any calcium supplementation. After recruitment each participant was 
taught how to take the drug in the prescribed dose from the sachet. Since cholecalciferol is 
unstable, once the sachet was opened and used, the remaining granules were discarded. Each 
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participant was contacted in person by the principal investigator, weekly once to ensure they 
were compliant and taking the drug in the prescribed way. 
 
        We monitored anthropometry and parameters like Se calcium, Se phosphorous, S 
alkaline phosphatase, Se parathyroid hormone level, and Se 25OHD at the time of 
recruitment, 8 weeks and 14 weeks after recruitment. To look for any toxicity Se calcium 
and urine spot calcium/creatinine ratio were done at  the 3
rd
 week , 8
th
 week and 14
th
 week 
after the initiation of supplementation. 
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ANALYTICAL METHODS: 
Vitamin D: 
Vitamin D levels in serum were assayed using the Sandwich electrochemiluminescence 
immunoassay (Automated Roch modular E170). 
 
Test principle: Competition principle 
 
Sample processing: Due to possible evaporative effects samples must preferably be 
measured with in two hours 
 
Measuring range:  4-100ng/ml (10-250nmol/L) 
Lower detection limit – 4ng/ml 
Upper detection limit – 100 ng/ml 
 
Interference: 
Samples showing visible signs of haemolysis (Haemoglobin concentrations >0.1g/dl) may 
cause falsely elevated results. Assay unaffected by icterus, lipemia and biotin or 
Rheumatoid factor. 
 
Reliability: 
Reliability of the vitamin D assay used for the study was assessed using the Intraclass 
correlation co-efficient (ICC) 
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 Se Calcium, Se ALP and Se Phosphorous analysis was carried out in Roche modular P800. 
 
Se Calcium: 
 
   Test principle: calorimetric end point method. Calcium forms purple coloured comples 
with o-cresol phthalein complexone in an alkaline medium. The intensity of the colour 
measured at 540nm is propotional to the Se Calcium. This measures total calcium in the 
blood. 
 
 
Se Phosphorous: 
 
  Test principle: Inorganic phosphate reacts with ammonium molybdate and sulphuric acid 
to form unreduced phosphomolybdate complex. The absorbance of this complex at 340nm 
is propotional to the inorganic phosphorous in the blood. 
 
 
 
Se Alkaline phosphatase: 
 
  Test principle: ALP is measured by hydrolysis of 4-nitrophenyl phosphate in alkaline ph. 
The substrate is converted to 4-nitro phenol in alkali with increased absorbance at 
415nm,this being propotional to ALP activity in the blood. 
 
40 
 
Se PTH: 
 
 Test principle: PTH is analysed by chemiluminescence method ( Siemens ADVIA Centaur 
automated chemiluminescence instrument, Siemens Healthcare Diagnostics, Deerfield, IL) 
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Table 4: Parameters monitored during the study period: 
 At recruitment     3
rd
 week       8
th
 week        14
th
 week 
Weight/ Height                                  
BMI/BMI centile                                  
Se. Calcium                                        
Se.Phosphorous                              
Se.Alkaline phosphatase                            
Se.25OHD                            
Se.PTH                            
Se.Albumin                    
Se.Creatinine                                  
Urine spot calcium/ 
creatinine ratio 
                                    
  
    
    
       This table depicts the various monitored parameters that were evaluated at each visit for 
the participants. We monitored anthropometry, Se calcium, Se phosphorous, Se alkaline 
phosphatase, Se parathyroid hormone level, and  Se 25OHD at the time of recruitment,          
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8 weeks and 14 weeks after initiation of supplementation.  The Se. calcium and urine spot 
calcium/creatinine ratio was done at 3
rd
 week , 8
th
 week and 14
th
 week after initiation of 
supplementation to look for any features of hypervitaminosis D. 
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STATISTICAL ANALYSIS:  
    Baseline characteristics were analysed and summarized according to the three trial arms. 
Continuous variables are summarized as mean (SD) or median (IQR) if non-normal 
distribution was present. Categorical characteristics were summarized with frequencies and 
percentages. Error plots were done to see how mean or median level changes in the outcome 
variables over time by the three treatment arms. Changes in Se 25OHD, Se PTH, Se alkaline 
phosphatase, Se calcium, Se phosphorous levels over time were assessed by three treatment 
arms using repeated analysis of covariance (ANCOVA), adjusted for age and gender. 
Statistical analyses were carried out using statistical package for social sciences (SPSS 
version 18 (SPSS Inc., Chicago, IL, USA)) and STATA. All tests were two-tailed and 
P<0.05 was considered significant.  
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SAMPLE SIZE CALCULATION: 
     Sample size was calculated based on difference between two means. 
      Sample size(n) = 2 SD
2 
 (Zalpha + Z beta)
2 
             [ SD- standard deviation 
                                           (M1-M2)                               Zalpha
_
type I error = 1.96 
                                                                                          Zbeta – type II error= 0.84 
                                                                                                   M1/M2- mean ] 
                                  
                              = 2 x 5
2 
x (1.96 + 0.84)
2
                [SD-5;  M1-M2: 5]* 
                                           5
2
 
                             = 16 in each group (total in 3 groups - 48) 
 *based on previous studies(48) 
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ETHICS APPROVAL:  
Institutional ethics committee(The Instituional Review Board, Christian Medical College, 
Vellore) approval was obtained and all subjects gave written informed consent. 
 
CLINICAL TRIAL REGISTRY-INDIA: 
    Our study was registered in Clinical Trial Registry-India, after getting approval from The 
Instituional Review Board and Ethics Committee, Christian Medical College, Vellore. 
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                                                RESULTS 
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     We recruited 39 asymptomatic children with vitamin D level less than 20ng/ml.  The 
details of each participant regarding demographic profile, past and current medical ailments, 
weight, height, Body Mass Index(BMI) and BMI centiles were gathered. The details 
regarding duration of and factors limiting sunlight exposure, like clothing, sunscreen etc 
were also recorded. 
        They were randomized based on block randomization into three groups.            
                      Group A: 6000 units oral cholecalciferol daily 
                      Group B: 10,000 units oral cholecalciferol daily 
                      Group C: 60,000 units oral cholecalciferol weekly 
Table 5: Study population and Treatment Group; 
                Treatment Group                     n(%) 
           Group A 
           Group B 
           Group C 
                13(33%) 
                11(28%) 
                15(39%) 
 
 
      Five participants in the entire study weighed  < 15kg (Group A-2, Group B-1 and Group 
C-2). The baseline characteristics of the participants in the different study groups are 
summarised in Table 6 and 7.  
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Table-6 : Baseline demographic and clinical characteristics of the study population 
compared across the groups: 
     GROUP A (n=13) 
             n (%) 
     GROUP B (n=11) 
                 n (%) 
     GROUP C (n=15) 
               n (%) 
   Gender 
            Male 
            Female 
 
              
              9(69) 
              4(31) 
 
 
               3(27) 
               8(73) 
 
 
              5(33) 
            10(67) 
 
 
 
 
        GROUP A 
        Mean(SD) 
         GROUP B 
         Mean(SD) 
       GROUP C 
       Mean(SD) 
    
Age (yrs) 
 
Weight (Kg) 
 
BMI 
 
BMI centile 
 
          9.1(4.5) 
 
        27.7(12.4) 
 
       16.7(2.6) 
 
   45.3 (15.1-68.0)* 
 
 
          9.8(3.0) 
 
         34.8(14.3) 
 
        20.5(5.1) 
 
       81(35.0-95.0)* 
 
 
          10.4(4.2) 
 
           38.3(18.2) 
 
          19.9(6.3) 
 
       47.2(14.4-86.4)* 
SD-standard deviation   IQR: Interquartile range      BMI-body mass index     
*to read as median(IQR) 
 
        The mean age at recruitment was 9.1 ± 4.5 yrs in group A (range:2.5-15yrs), 9.8 ± 3.0 
yrs in group B (range:3.5-12.5yrs) and 10.4 ± 4.2yrs in group C (range 2.0-15.0yrs).  In 
group B and group C , the predominant population were females (73% and 67% 
respectively), while in group A  males were more predominant (69%) (Fig 3).  
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Fig 3: GENDER DISTRIBUTION :Demonstrating predominant population of females(73% 
and 67%) in group B and group C, and males (69%)  in group A.  
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Fig 4: DISTRIBUTION OF OVERWEIGHT/OBESE BETWEEN THE GROUPS:  
 
 
            The median BMI centile  in Group A and Group C were  similar (45.3 and 47.2)  
compared to Group B (81). Twenty  nine children (74%)  had BMI <85
th 
centile (Group A-
12, Group B-6 and Group C-11). Nine children (26%) had BMI > 85
th
 centile (Group A-1, 
Group B-5 and Group C-4). 
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Table-7 : Baseline biochemical characteristics of the study population compared across the 
groups: 
 
 
        GROUP A 
        Mean (SD) 
         GROUP B 
         Mean (SD) 
       GROUP C 
       Mean (SD) 
    
 
 
Se Calcium (mg/dl) 
 
Se Phosphorous (mg/dl) 
 
Se ALP (U/L) 
 
Se 25OHD (ng/ml) 
 
Se PTH (pg/ml) 
 
           
 
       9.1 (0.4) 
 
      4.9 (0.7) 
 
     195.6 (55.1) 
 
     15.6 (4.1) 
 
   56.2 (43.5-62.0)* 
 
 
 
        9.1 (0.5) 
 
        4.8 (0.6) 
 
       193.9 (48.1) 
 
      12.2 (3.9) 
 
   54.0 (35.0-95.0)* 
 
           
 
          9.1 (0.4) 
 
           4.9 (0.7) 
 
         173.9 (45.8) 
 
         13.0 (4.3) 
          
     34.6 (14.4-86.4)* 
 
Se PTH-parathyroid hormone        Se 25 OHD- 25 hydroxy vitamin D                                                 
Se ALP-  Alkaline phosphatase      SD-standard deviation   IQR: Interquartile range       
*to read as median (IQR) 
       
     The mean Se 25OHD level at recruitment was 15.6 ± 4.1 ng/ml in group A, 12.2 ± 3.9 
ng/ml in group B and 13.0 ± 4.3 ng/ml in group C. The mean calcium value was similar in 
all the groups. The median Se PTH value in group A and group B were almost similar (56.2 
pg/ml and 54.0 pg/ml) compared to low median value in  Group C (34.6 pg/ml).  
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 THIRD WEEK PARAMETERS: 
         At the third week of therapy, 22 (56%) participants were screened for Se Calcium and 
urine spot calcium/creatinine ratio. Four participants (Group A: n=1 and Group C-n=3)  had 
elevated urine spot calcium/creatinine ratio but Se Calcium was within normal range and 
there were no other features of hypervitaminosis D.   
 
 
 
 
 
EIGHTH WEEK PARAMETERS: 
             At 8
th
 week , 31 participants (79%) were followed up (Group A-11 out of 13, Group 
B-8 out of 11and Group C-12 out of 15).  Biochemical parameters done for the study 
participants in the eighth week are summarized in Table 8. 
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Table 8: EIGHTH WEEK PARAMETERS COMPARED BETWEEN GROUPS:  
 
 
  GROUP A (n=11) 
        Mean (SD) 
    GROUP B (n=8) 
         Mean (SD) 
   GROUP C (n=12) 
       Mean (SD) 
    
Se Calcium (mg/dl) 
 
Se Phosphorous (mg/dl) 
 
Se ALP (U/L) 
 
Se 25 OHD (ng/ml) 
 
Se PTH (pg/ml) 
 
        9.2 (0.4) 
 
       4.6 (0.6) 
 
      177.0 (58.2) 
 
      59.1 (17.3) 
 
   25.3 (21.0-39.7)* 
 
          9  (0.3) 
 
         4.6 (0.7) 
 
       196.6 (43.7) 
 
       47.0 (10.0) 
 
   34.8 (31.7-44.1)* 
 
           9.3 (0.4) 
 
           4.3 (0.9) 
 
         157.2 (36.8) 
 
         51.9 (10.1) 
          
     35.4 (14.3-39.7)* 
 
SD-standard deviation    BMI-body mass index      Se  PTH-parathyroid hormone                             
Se 25 OHD- 25 hydroxy vitamin D3        Se ALP-  Alkaline phosphatase                           
IQR: Interquartile range       
*to read as median (IQR) 
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   The mean Se 25OHD level at the eighth week was 59.1 ± 17.3 ng/ml in group A,  47.0 ± 
10.0 ng/ml in Group B and 51.9 ± 10.1 ng/ml in group C. Paradoxically though group B 
received the highest total supplementation (cumulative dose), an expected maximal rise was 
not seen. The mean Se calcium was similar in all the groups (Group A: 9.2 ± 0.4 mg/dl, 
Group B: 9.0 ±  0.3 mg/dl and Group C: 9.3 ± 0.4 mg/dl). The median PTH was similar in 
Group B (34.8 pg/ml) and Group C (35.4 pg/ml) compared to Group A (25.3 pg/ml). The 
mean Se Phosphorous was also similar in all the groups (Group A: 4.6 ± 0.6 mg/dl, Group 
B: 4.6 ± 0.7 mg/dl and Group C: 4.3 ± 0.9 mg/dl). The mean Se ALP was 177 ± 58.2 U/L in 
Group A, 196 ± 43.7 U/L in Group B and 157 ± 36.8 U/L in Group C. The urine spot 
calcium/ creatinine ratio was normal for all the participants in the eighth week. The elevated 
urine spot calcium/ creatinine ratio observed in the third week normalized by the eighth 
week. 
  
FOURTEENTH  WEEK PARAMETERS: 
            Six weeks after the last supplementation, clinical and biochemical parameters were 
re-analysed.  Thirty four children (87%) were followed up (Group A-11 out of 13, Group B-
9 out of 11and Group C-14 out of 15).  Biochemical parameters done for the study 
participants in the fourteenth week are summarized in Table 9. 
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Table 9: FOURTEENTH WEEK PARAMETERS COMPARED BETWEEN GROUPS: 
 
 
  GROUP A (n=11) 
        Mean (SD) 
    GROUP B (n=9) 
         Mean (SD) 
   GROUP C (n=14) 
       Mean (SD) 
    
Se Calcium (mg/dl) 
 
Se Phosphorous (mg/dl) 
 
Se ALP (U/L) 
 
Se 25 OHD (ng/ml) 
 
Se PTH (pg/ml) 
 
        9.1 (0.3) 
 
       4.6 (0.6) 
 
      193.2 (69.1) 
 
      45.5 (13.6) 
 
  35.1 (30.7- 44.1)* 
 
          9.0 (0.5) 
 
         4.7 (0.5) 
 
       194.7 (40.7) 
 
       32.0 (8.5) 
 
  38.6 (32.1- 48.2)* 
 
           9.1 (0.4) 
 
           4.5 (0.8) 
 
         178.7 (46.6) 
 
         44.7 (15.6) 
          
     40.6 (34.6-52.4)* 
 
SD-standard deviation    BMI-body mass index    Se. PTH-parathyroid hormone                             
Se.25 OHD- 25 hydroxy vitamin D3        Se.ALP-  Alkaline phosphatase                             
IQR: Interquartile range      *to read as median (IQR) 
 
        The mean Se 25OHD levels at the fourteenth week were similar in Group A (45.5 ± 
13.6 ng/ml) and Group C (44.7 ± 15.6 ng/ml) compared to Group B (32.0 ± 8.5 ng/ml). The 
mean Se Calcium was normal and similar in all the groups (Group A:9.1 ± 0.3 mg/dl, Group 
B: 9.0 ± 0.5 mg/dl and Group C: 9.1 ± 0.4 mg/dl). The median PTH value in Group A was 
35.1 pg/ml, in Group B was 38.6 pg/ml and in Group C was 40.6 pg/ml . The Se 
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Phosphorous was similar in all the groups (Group A: 4.6 ± 0.6 mg/dl, Group B: 4.7± 
0.5mg/dl and Group C-4.5 ± 0.8mg/dl). The mean Se ALP was similar in Group A (193.2 ± 
69.1U/L) and Group B (194.7 ± 40.7 U/L) compared to Group C (178.7 ± 46.6 U/L). The 
urine spot calcium/creatinine ratio was normal for all the participants in the fourteenth week. 
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                         DISCUSSION 
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We recruited 39 children with Se 25OHD less than 20ng/ml. They were evaluated for  
features of rickets clinically and for evidence of secondary causes that interfere with vitamin 
D absorption or metabolism. The predominant secondary causes that interefere with vitamin 
D absorption and metabolism in children are malabsorption syndrome, chronic renal disease 
and chronic liver disease. We screened all the participants for Se albumin and Se creatinine 
to rule out chronic renal disease and chronic liver disease. Se albumin and Se creatinine 
were normal for all the children and there were no features of rickets or malabsorption in 
any of the participants.  
 
 
       Among the 39 children, 22 were females (56%) and 17 were males (44%). In groups B 
and C, the predominant population was females (73% and 67% respectively), while in group 
A, males(69%) were more (Fig 3). The mean age (Table 6) at recruitment was similar in all 
groups [Group A: 9.1 ± 4.5 (range: 2.5-15) yrs, Group B: 9.8 ± 3.0 (range: 3.5-12.5) yrs and 
Group C: 10.4 ± 4.2 (range: 2.0-15) yrs). Only five participants could be recruited who 
weighed less than 15 kg (Group A-n=2, Group B-n=1 and Group C-n=2).  In view of the 
non-normal distribution for BMI centiles and Se PTH, we have analyzed the median (IQR) 
(and not mean, SD) for these parameters. The median BMI centile in group A (45.3 pg/ml) 
and Group C (47.2 pg/ml) were similar, and comparatively lower than Group B (81 pg/ml)..  
Most of the participants had BMI less than <85
th
 centile. In Group A, one (7%) out of 13, in  
Group B, 5 (45%) participants out of 11 were above the 85
th  
centile for BMI and in Group 
C, 4 participant out of 15 (26%) were above the 85th centile for BMI (Fig 4). The mean Se 
25OHD at recruitment was 12-16 ng/ml (Group A: 15.6 ± 4.1ng/ml, Group B: 12.2 ± 3.9 
ng/ml and group C 13.0 ± 4.3 ng/ml). The median Se PTH was similar in Group A (56.2 
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pg/ml) and Group B (54.0 pg/ml) and comparatively higher than Group C (34.6pg/ml). The 
mean Se Calcium and Se Phosphorous were similar in all the groups(Table 7). 
    
               The amount of UVB radiation available from sunlight depends on the angle at 
which the sun‟s rays strike the earth which in turn depends on the latitude of the place. We 
recruited participants from in and around Vellore (Latitude 12° 55' N), so that participants 
were limited to a similar latitudinal area.   In our study, as our participants were recruited 
throughout the year based on block randomization serially, the influence of seasonal bias on 
the treatment groups results is possibly avoided .  
 
                 Though Se 25OHD is not the active form of Vitamin D, it is the major circulating 
form and it depicts the invivo status of vitamin D (47). A minimal alteration in Se Calcium 
can cause reciprocal PTH changes maintaining normal or increased 1,25 dihydroxy vitamin 
D3 (which is the active form of vitamin D) even when the body is actually deficient in 
Vitamin D (2). Moreover the half-life of 1,25 dihdroxy vitamin D3 is only 4 hours, 
compared to 3-4 weeks in case of 25OHD (2). Endocrine Society Clinical Practice 
Guidelines recommend using Se 25OHD as a reliable marker for vitamin D status and not 
1,25 dihydroxy vitamin D3.   
 
     Optimum Se 25OHD level in the blood is still controversial. In 1997, American 
Academy of Pediatrics defined vitamin D deficiency as Se 25OHD level less than 11ng/ml 
(46). Since then it has been revised several times and currently, the most accepted definition 
for vitamin D deficiency is Se 25OHD less than 20ng/ml (2,47,48). This is based on the 
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evidence that Se PTH remains suppressed only when Se 25OHD level is more than 20ng/ml 
and rickets/osteomalacia rarely occurs when Se 25OHD is more than 20ng/ml (47). In a 
study done by Clianferotti et al,(50) it is preferable to maintain vitamin D level above 
75nmol/L (30ng/ml) to maximize the effects of vitamin D on musculoskeletal system. 
Haroon et al(51) also showed that higher levels of vitamin D is required to maintain 
adequate musculoskeletal health. Holick et al(47) suggest that vitamin D level more than 
30ng/ml is required to satisfy the VDR receptor cellular level to maintain adequate 
extraskeletal health. Endocrine Society Clinical Practice Guidelines suggest Se 25OHD less 
than 20ng/ml as vitamin D deficiency and levels between 21-29 ng/ml as vitamin D 
insufficiency to stress the importance of maintaining adequate vitamin D level more than 30 
ng/ml for optimum musculoskeletal and extraskeletal health (47). In our study we 
considered Se 25 OHD level less than 20 ng/ml as vitamin D deficiency as per the 
guidelines. 
    
       Armas et al(62) compared the effectiveness of vitamin D2 with vitamin D3 after a 
single oral dose of 50,000 units and found that the initial response was similar in both 
groups, but Se 25OHD continued to rise in vitamin D3 group compared to vitamin D2 
group, in which Se 25OHD level tend to fall after 3 days and reach the pretreatment level by 
day 14. Logan et al(63) also showed that long term cholecalciferol supplementation is more 
effective than vitamin D2 in maintaining Se 25OHD level..  
      
.      In vitamin D deficiency, Endocrine Society Clinical Practice Guidelines recommend 
2000 units daily of vitamin D2 or vitamin D3 for 6 weeks or 50,000 units of vitamin D2 
weekly once for 6 weeks to attain Se 25OHD level more than 30ng/ml(47). Vitamin D 
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toxicity was observed when the dose exceeded 10,000 units daily(77) or if single oral dose 
exceeded 3 lakh units(78). In our study, we compared three oral cholecalciferol 
supplementation therapies- 6000 units daily (Group A), 10,000 units daily (Group B) and 
60,000 units weekly (Group C). We used half the dose of cholecalciferol for children 
weighing less than 15kg (i.e) 6000 units alternate day in group A, 10,000 units alternate day 
in group B and 30,000 units weekly once in group C  as studies have shown that lower dose 
of vitamin D is sufficient to have adequate response in infants and toddlers (48) and these 
dosing schedules fall well within the standard recommendations for treatment of vitamin D 
deficiency.  
 
      Armas et al(62) showed that peak response after oral administration of vitamin D3 occur 
approximately after 14 days and Se 25OHD level tend to fall by 1 month and then reach the 
baseline by 2-3 months. We analyzed the participants at 8
th
 week (2 weeks after completion 
of the total supplementation, expecting the peak response at that time) to compare the peak 
response between the groups in raising Se 25OHD level. We again analyzed them at  14
th
 
week of the study (8 weeks after completion of supplementation) to compare the 
effectiveness between the groups in maintaining steady state of Se 25OHD.  The 
biochemical parameters measured at 8
th
  was summarized in  Table 8.. 
 
                 At 8
th
 week of study,  the mean Se 25OHD level at was 59.1 ± 17.3 ng/ml in 
group A,  47.0 ± 10.0 ng/ml in Group B and 51.9 ± 10.1 ng/ml in group C. The mean Se 
calcium was similar in all the groups (Group A: 9.2 ± 0.4 mg/dl, Group B: 9.0 ±  0.3 mg/dl 
and Group C: 9.3 ± 0.4 mg/dl). The median PTH was similar in Group B (34.8 pg/ml) and 
Group C (35.4 pg/ml) compared to Group A (25.3 pg/ml). The mean Se Phosphorous was 
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also similar in all the groups (Group A: 4.6 ± 0.6 mg/dl, Group B: 4.6 ± 0.7 mg/dl and 
Group C: 4.3 ± 0.9 mg/dl). The mean Se ALP was 177 ± 58.2 U/L in Group A, 196 ± 43.7 
U/L in Group B and 157 ± 36.8 U/L in Group C. The urine spot calcium/ creatinine ratio 
was normal for all the participants in the eighth week.  
        
          All three treatment protocols showed approximately four fold rise in mean Se 25OHD  
level from the baseline(Group A:15.6 to 59.1ng/ml; Group B: 12.2 to 47.0 ng/ml; and Group 
C: 13.0 to 51.9 ng/ml)(Table 8). In a study done by  Catherine M et al(48) comparing  daily 
dosing of vitamin D2 and vitamin D3 with weekly dosing of vitamin D2, the findings were 
similar to our study(i.e), there was three fold rise in Se 25OHD in all  the participants 
irrespective of the treatment protocol.  The mean response of  Se 25OHD (increase in         
Se 25OHD) from the time of recruitment to 8
th
 week was analysed using ANCOVA and 
found that mean change of Se 25OHD in group A (43.8 ± 17.5 ng/ml) was higher than 
group C (38.3 ± 11.0 ng/ml) and Group B (34.2 ± 9.2 ng/ml) (Table 7).  The mean response 
of Se 25OHD  at eighth week from the time of recruitment is summarized in Table 10.  
 
 
 
 
 
63 
 
Table 10:  Vitamin D response(change in vitamin D level) from 0-8
th
 week: comparision 
between groups. 
Vitamin D 
response 
   Group A  
      (n=11) 
  Mean (SD) 
    Group B  
    (n=8) 
 Mean (SD) 
    Group C  
     (n=12) 
    Mean (SD) 
      p value 
 
 0-8
th
 week 
        
     43.8 (17.5) 
        
     34.2 (9.2) 
        
     38.3 (11.0) 
 
        0.30 
 
        
       Though Group A showed better response at 8
th
 week , there is no statistically significant 
difference in response between the groups (p=0.30).  Paradoxically the group which has 
received the maximum cumulative dose(Group B) has shown lesser response compared to 
other groups, but this is also statistically non significant(p=1).  
   
             The mean reciprocal decline in the Se PTH value from the time of recruitment to 8
th
 
week in Group B (-30.9 ± 36.5 pg/ml) was more than Group A (-25.5 ± 17.6 pg/ml) and 
Group C (-17.1 ± 17.6 pg/ml), but Jonckheere-Terpstra Test analysis showed that the 
response is not statistically significant (p=0.172). The improvement in Se alkaline 
phosphatase was observed in all the groups but  the difference between the groups was not 
statistically significant (p=0.7). The spot urine calcium/creatinine ratio was within normal 
range for all the participants at  the 8
th
 week of the study. 
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FOURTEENTH WEEK: 
           Thirty four children (87%) were followed up (Group A-11 out of 13, Group B-9 out 
of 11and Group C-14 out of 15).  Biochemical parameters done for the study participants in 
the fourteenth week are summarized in Table 9. 
    
           The mean Se 25OHD levels at the fourteenth week were similar in Group A (45.5 ± 
13.6 ng/ml) and Group C (44.7 ± 15.6 ng/ml) compared to Group B (32.0 ± 8.5 ng/ml). The 
mean Se Calcium was normal and similar in all the groups (Group A:9.1 ± 0.3 mg/dl, Group 
B: 9.0 ± 0.5 mg/dl and Group C: 9.1 ± 0.4 mg/dl). The median PTH value in Group A was 
35.1 pg/ml, in Group B was 38.6 pg/ml and in Group C was 40.6 pg/ml . The Se 
phosphorous was similar in all the groups (Group A: 4.6 ± 0.6 mg/dl, Group B: 4.7± 0.5 
mg/dl and Group C-4.5 ± 0.8 mg/dl). The mean Se ALP was similar in Group A (193.2 ± 
69.1U/L) and Group B (194.7 ± 40.7 U/L) compared to Group C (178.7 ± 46.6 U/L).  
      Comapred to  the baseline values, Se 25OHD was maintained within normal range at the 
end of the study (2 months after discontinuation), the difference in the degree of response 
being statistically non-significant. The Se 25OHD and Se PTH compared between 8
th
 and 
14
th
 week in each group was summarized in table 11,12 and 13. 
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Table 11: Treatment group A-  Vitamin D and PTH measured at 8
th
 and 14
th
 week 
    
          8
th
  week (n=11) 
              Mean (SD) 
 
              14
th
 week (n=11) 
                 Mean (SD) 
 
   
Se Vitamin D (ng/ml) 
 
Se PTH (pg/ml) 
 
 
           59.1 (17.3) 
 
          25.3(21.0-39.7)*    
 
             
             45.5 (13.6) 
 
            35.1(30.7-44.1)* 
 
SD-standard deviation    Se PTH-parathyroid hormone                                                                        
Se 25 OHD- 25 hydroxy vitamin D3            IQR: Interquartile range       
*to read as median (IQR) 
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 Table 12: Treatment group B- Vitamin D and PTH measured at 8
th
 and 14
th
 week 
    
             8
th
  week(n=8) 
               Mean(SD) 
 
              14
th
 week(n=9) 
                 Mean(SD) 
 
 
 Se 25OHD (ng/ml) 
 
Se PTH (pg/ml) 
 
 
            47.0(10.0)    
 
           34.8 (31.7-44)* 
 
 
             32.0(8.5) 
 
             38.6(32.1-48.2)* 
 
SD-standard deviation    Se PTH-parathyroid hormone                                                                         
Se 25 OHD- 25 hydroxy vitamin D3            IQR: Interquartile range       
*to read as median (IQR) 
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OBJECTIVES:  
     The objective was to compare effectiveness of three different vitamin D supplementation 
protocols and to establish the effective protocol with minimal side effects for asymptomatic 
vitamin D deficient children.  
 
 
METHODS: 
Children (1-18years) with asymptomatic hypovitaminosis  D (serum 25OHD <20ng/ml) were 
randomized into 3 different oral cholecalciferol supplementation protocols (6000 units 
daily/10,000 units daily/60,000 units weekly once) for  6 weeks. Clinical and biochemical 
(including serum 25OHD, calcium) parameters were monitored at baseline, 2weeks and 8 weeks 
after completing treatment.  The results were analyzed with repeated measures analysis of 
covariance (ANCOVA) using statistical package for social sciences (SPSS) and STATA. 
 
RESULTS: 
 
      Thirty nine children with serum 25OHD <20 ng/ml were randomized into the 3 
cholecalciferol supplementation protocols as above. All the treatment groups showed similar 
improvement in serum 25OHD level 2 weeks after completion of treatment. Children with BMI >  
85th centile showed a lower increase in serum 25OHD level for a particular dose of 
cholecalciferol as compared to children with BMI <85th centile (p=0.02). Hypercalciuria was 
observed during the initial weeks of supplementation in  four participants especially in the group 
receiving the high dose weekly oral cholecalciferol.  Hypercalciuria improved over next couple of 
weeks. 
 
CONCLUSIONS:  
Oral   cholecalciferol 6000 units daily; 10,000 units daily and 60,000 units weekly once; for 6 weeks) showed 
similar efficacy in raising Se 25OHD levels in asymptomatic children with hypovitaminosis D without any 
toxicity.  BMI has a significant influence on the treatment response during the initial phase (i.e.) children with 
BMI >  85th centile require a higher dose of cholecalciferol for a similar rise in Se 25OHD as compared to 
children with BMI <85th centile. 
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Table 13: Treatment group C- Vitamin D and PTH measured at 8
th
 and 14
th
 week 
    
            8
th
  week (n=12) 
                Mean (SD) 
 
             14
th
 week (n=14) 
                  Mean (SD) 
 
   
 Se 25OHD (ng/ml) 
 
Se PTH (pg/ml) 
 
       
           51.9 (10.1)   
 
           35.4 (14.3-39.7)* 
 
     
             44.7 (15.6) 
 
            40.6 (34.6-52.4)* 
 
SD-standard deviation    Se PTH-parathyroid hormone                                                                          
Se 25 OHD- 25 hydroxy vitamin D3            IQR: Interquartile range       
*to read as median (IQR) 
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      At 14
th
 week of the study (8 weeks after completion of the treatment), there is a decline 
in Se 25OHD in almost all the participants as expected, except two children in group C who 
showed increase in Se 25OHD from the 8
th
 week values. This decline in Se 25OHD at 8 
weeks after cessation of Vitamin D supplementation reiterates the recommendation for 
continuation of supplementing daily requirements or adopting better sunlight exposure 
practices. The mean change in Se 25OHD from the 8
th
 week to 14
th
 week is summarized in 
Table 14.  
 
 
Table 14:  Vitamin D response (decline in vitamin D level) from 8
th
-14
th
  week: comparision 
between groups 
Vitamin D 
response 
   Group A  
      (n=11) 
  Mean (SD) 
    Group B  
    (n=9) 
 Mean (SD) 
    Group C  
     (n=14) 
    Mean (SD) 
      p value 
 
8
th
 -14
th
 week 
 
        
   13.5 (10.3) 
        
    14.5 (7.9) 
         
    5.8 (10.1) 
 
       0.009 
 
 
 
         The mean decline in Se.25OHD from 8
th
 to 14
th
 week was analysed using ANCOVA 
and found that the mean change was less in Group C (5.8±10.1ng/ml) compared to Group A 
69 
 
(13.5 ± 10.3 ng/ml) and Group B(14.5 ± 7.9 ng/ml)  which was statistically significant 
(p=0.009) (Table 14). There is paucity of literature in this aspect in children. In adults daily 
versus weekly dosing has found variable results regarding stability of 25OHD levels after a 
few weeks of supplementation.  In other words, Se 25OHD  levels were maintained for a 
longer time with weekly dose as compared to a similar magnitude of daily dose regimen 
after discontinuation of cholecalciferol supplementation.  As expected there is relative 
increase in Se PTH in all the groups at 14
th
  week,  but  Jonckheere-Terpstra test didn‟t show 
significant difference between the groups (p=0.117).   
         
        The overall Se 25OHD response across the study period was studied using repeated 
measure analysis variance and post Hoc test of comparision using Boneferroni correction 
(Table 15), which showed no significant difference (Group A vs Group B:p=0.8; Group B 
vs Group C:p=0.3; Group A vs Group C:p=1.0) between the treatment groups , though the 
graph(Fig 5) depicts response was better in Group A  in initial 8 weeks(statistically non 
significant, p=0.3)) and thereafter stable level of Se 25OHD was achieved in Group C, 
(statiscally significant,p=0.009).  
 
 
 
 
 
70 
 
 
 
 
Table 15: Vitamin D response over a period of 14 weeks: Intergroup comparision (Post Hoc 
comparision using BONFERONI): 
TREATMENT GROUP  TREATMENT GROUP 
Std. Error Sig. 
 Group A         Group B 3.95 .08 
        Group C 3.55 1.0 
Group B         Group A 3.95 .08 
        Group C 3.88 .33 
Group C         Group A 3.55 1.0 
        Group B 3.88 .33 
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FIG 5: Se 25OHD RESPONSE OVER THE STUDY PERIOD (0-14
TH
 WEEK): 
COMPARED BETWEEN THE GROUPS 
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  INFLUENCE OF BMI ON TREATMENT: 
         Twenty nine participants who were <85
th
 BMI centile showed greater response of       
Se 25OHD at 8
th
 week of supplementation (42.9 ± 13.4 ng/ml) compared to children who 
were >85
th
 centile (28.3 ± 5.2 ng/ml), irrespective of the treatment group and this difference 
was statistically significant (p=0.02) (Table 16). Similar results have also been documented 
by Sioen et al(76) who showed that BMI has significant influence on vitamin D status in 
young Belgian childrens. In another study done by  Saliba et al(72), BMI was shown to have 
inverse relation with vitamin D response on vitamin D supplementation.  This is similar to 
our observation (i.e) children with BMI <85
th
 centile showed better response compared to 
those with BMI>85
th
 centile.This has a practical significance that children who are 
overweight and obese require higher doses of vitamin D to achieve a similar increase in       
Se 25OHD as compared to non-obese children. With this significant finding, we recommend 
that vitamin D supplementation doses should be based on BMI rather than weight or age of 
the  patient.  Larger cohorts need to be studied to reconfirm this association and to make 
recommendations on dosing of Vitamin D.  
 
           The Se 25OHD decline between 8
th
 to 14
th
 week (after stopping the supplementation) 
was not significantly influenced by the BMI centile (p=0.12) (FIG 7). The overall (baseline 
to 14 weeks) Se 25OHD response across the study period was analysed using repeated 
measure analysis (ANCOVA) and BMI centile did not have a significant correlation 
(p=0.74).  The mean change of Se 25OHD from 0- 8
th 
 week and 8
th
-14
th
 week compared 
between BMI centile <85 and BMI centile > 85 is summarized in table 16. 
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Table 16: Influence of BMI (centile) on vitamin D response between 0-8
th
 week and 8
th
 -14
th
 
week:  
Vitamin D response    BMI centile <85 
           n=23 
        Mean(SD) 
   BMI centile >85 
          n=8 
      Mean(SD) 
      p value 
 
 0-8
th
 week 
        
     42.9(13.4) 
        
      28.3(5.2) 
 
        0.02 
 
8
th
 -14
th
 week 
 
        
   11.9(11.2) 
        
      7.4(5.9) 
 
       0.12 
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 INFLUENCE OF AGE AND GENDER ON TREATMENT: 
     
    Using repeated analysis of covariance, we analysed the correlation between Se 25OHD 
and age and with gender. We found that age (p=0.9) and gender (0.08) had no significant 
influence on treatment response.  Endocrine Society Clinical Practice Guidelines 
recommend uniform dose for children (with vitamin D deficiency) from 1-18 yrs (47). The 
preplanned comaparision between children weighing <15kg and >15 kg could not be done 
in view of the small size of the sample <15 kg. 
 
 
 
INFLUENCE OF  SEVERITY OF BASELINE VITAMIN D DEFICIENCY ON 
TREATMENT: 
     
      We analyzed the association of severity of baseline vitamin D deficiency (Se 25OHD 
level) on treatment response using repeated measure analysis of covariance. The severity of 
Vitamin D deficiency at recruitment doesn‟t show any influence on the treatment response  
(p=0.3) and there is paucity of literature in this aspect in children.  Further research is 
needed to compare the severity of vitamin D deficiency and treatment response and also 
whether the supplementation should be based on the severity of vitamin D deficiency (Se 
25OHD level) rather than giving uniform treatment to all asymptomatic children 
irrespective of Se 25OHD level.   
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HYPERVITAMINOSIS D: 
     Misra et al suggested vitamin D excess as Se 25OHD >100 ng/ml and vitamin D 
intoxication as Se 25OHD >150 ng/ml. Jones G et al considered 250nmol/L (approximately 
100ng/ml)  of Se.25OHD as safety (upper) limit of vitamin D status (75). 
 
     Among 22 participants, who were screened at the 3
rd
 week of supplementation, four were 
found to have elevated urine spot calcium/creatinine ratio (Group A-1 and Group C-3), but 
there were no other clinical features of hypervitaminosis D. Moreover the Se Calcium was 
within normal range and Se 25OHD was within 100ng/ml in these children. The urine spot 
calcium/creatinine ratio of these four participants normalized in the subsequent sampling 
(next couple of weeks). At 8
th
 and 14
th
 week, Se Calcium, Se 25OHD and urine spot calcium 
creatinine ratio were normal in all the children.. 
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                        CONCLUSIONS 
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1. All the three Vitamin D supplementation protocols (oral cholecalciferol 6000units 
daily; 10,000 units daily and 60,000 units weekly once; for 6 weeks) showed similar 
efficacy in raising Se 25OHD levels and there was no statistically significant 
difference between the groups. 
 
2. The decline in Se 25OHD at 8 weeks after cessation of Vitamin D supplementation 
reiterates the recommendation for continuing supplementation of daily Vitamin D 
requirement or adopting better sunlight exposure practices. 
 
3. BMI has a significant influence on the treatment response during the initial 
phase(i.e.), children with BMI >  85
th
 centile require a higher dose of cholecalciferol 
for a similar rise in Se 25OHD as compared to children with BMI <85
th
 centile. 
 
4. There was no evidence of hypervitaminosis D as measured by Se 25OHD levels and     
Se calcium levels, but hypercalciuria was observed during the initial weeks of 
supplementation in a few participants especially in the group recieving the high dose  
weekly  oral cholecalciferol.   
 
5. Age, gender and baseline severity of vitamin D deficiency did not have a significant 
influence on the oral cholecalciferol treatment reponse. 
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                            LIMITATIONS 
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1. Since  our  sample size was small, we require further research adequately powered to 
authenticate our observation. 
 
2. Cholecalciferol granules were divided into 6000 units and 10,000 units in a crude way. 
The dosage taken by the participants may not be 100% accurate.. 
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                                             ANNEXURE  
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                                                    PROFORMA 
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RANDOMIZED TRIAL COMPARING THE EFFECT OF THREE DIFFERNT VITAMIN D SUPPLEMENTATION 
PROTOCOL IN VITAMIN D DEFICIENT  CHILDREN 
 
1. NAME:                                          2. SEX: MALE/FEMALE                    3. DATE OF BIRTH/ AGE: 
 
      4. RESIDENCE:                                     5. HOSPITAL NO: 
 
      6. PRIMARY DIAGNOSIS: 
 
     7. ANY OTHER ILLNESS: 
 
     8. MEDICATIONS: 
 
     9. SUNLIGHT EXPOSURE :  
 
                                          
                            SUNLIGHT EXPOSURE 
   BEFORE RECRUITMENT           AFTER RECRUITMENT 
       CLOTHING               
(BSA EXPOSED) 
  
 AVERAGE DURATION 
OF EXPOSURE PER DAY 
  
       SUNSCREEN   
   
 
    10. TREATMENT GROUP : 
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11. PARAMETERS: 
          TIME OF    
                  SAMPLING    
 PARAMETERS              
 
           0 WEEK 
 
       3rd  WEEK 
 
       8th  WEEK 
 
        14th  WEEK 
             DATE     
          Weight     
          Height     
      BMI and  BMI       
percentile 
    
       Se.Calcium     
    Se.Phosphorous     
         Se. ALP     
     Se.25 OHD     
        Se.PTH     
      Se. Albumin     
     Se. Creatinine     
Ur. Ca/creatinine 
ratio 
    
 
 
COMMENTS: 
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DATA SHEET
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ABBREVATIONS 
SEX: 1- Male   2-Female 
TREATMENT GROUP: 1- Group A    2-Group B     3-Group C 
BMI: Body mass index   
BMI%: Body mass index centile 
Se Ca: Serum calcium mg/dl 
Se Po4: Serum phosphorous mg/dl 
Se ALP: Serum alkaline phosphatase U/L 
Se PTH: Se Parathyroid hormone pg/ml 
Ur Ca/Creat: Urine spot calcium/creatinine ratio.
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S.NO 
AGE(YRS
) SEX 
TREATMEN
T GROUP 
WEIGH
T 1(KG) 
HEIGHT 
1(CM) BMI 1 BMI % 1 S.Ca 1 
1 8.5 1 3 48 114 36.9 99.7 9.4 
2 12 2 2 36.9 140 18.8 60 9.4 
3 12 1 1 32.3 147 14.9 5.2 9.1 
4 11.5 2 2 45.5 150 20.2 81 8.1 
5 15 1 3 79 163 29.7 97.6 9.2 
6 15 2 1 36.4 151 16 3.1 8.8 
7 12.5 2 3 37.4 135 20.6 77 9.4 
8 9 1 2 22 119 15.5 35 9.5 
9 2.5 1 1 9.4 84 13.3 0.1 9.7 
10 6 2 1 15 104 13.8 6.9 9 
11 3.5 2 2 13.5 97 14.3 10 9.8 
12 8 2 3 22.8 124 14.8 24 8.9 
13 15 1 1 43 145 21 58 9.1 
14 15 2 3 41 161 15.8 2.5 9.2 
15 12 2 2 37 140 19 61 9.4 
16 12.5 1 2 45 136 24.3 93.5 9.6 
17 12 1 1 38 147 18 46 9 
18 10.5 2 3 45 150 20 80 8.1 
19 3.5 2 1 13 92 15.5 45.3 9.8 
20 13 2 3 51.5 162 19.6 61.5 9.2 
21 15 2 3 39 152 16.8 9.5 9 
22 11 1 3 57 150 25.3 97.3 9.2 
23 13 2 1 38 150 16.8 22.2 8.2 
24 12 2 2 56 140 28.6 98.3 8.9 
25 5 1 1 15 94 16.6 81.5 9.2 
26 8 2 3 24 126 15.3 34 8.9 
27 6 2 2 15 105 13.6 7.5 8.2 
28 15 2 3 43 152 18.6 30 9 
29 7 1 1 25 116 17 78 9.2 
30 11 1 3 43 145 20.9 86.4 9.2 
31 12.5 1 2 40 134 22.2 89 9.4 
32 2 2 3 8.2 77 13.8 1.4 8.7 
33 9 1 1 38 129 22.8 96 9.5 
34 9.5 2 3 25.6 125 16.3 47.2 9.6 
35 10.5 2 2 49 131 28.5 95.1 9.3 
36 5 1 1 16 102 15.3 48 9.5 
37 14.5 1 1 42 161 16.2 6.7 9 
38 2 1 3 10.3 82 15.3 14.4 9.9 
39 7 2 2 23 105 20.8 95 9 
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S.NO S.Po4 1 S.ALP 1 S.Vit D 1 PTH 1 
WEIGH
T 8 
HEIGHT 
8 BMI 8 BMI % 8 
1 6 281 9.2 75.8         
2 4.8 188 12.2 54         
3 5.7 232 17.9 77.7 32 148 14.6 5.2 
4 4.2 206 7.7 72.1 46 151 20.2 80 
5 3.5 90 19.2 69.1 80 165 29.4 97.5 
6 4.3 60 6.59 62.2 36.5 151 16 3.1 
7 5.3 164 12.6 55.1 38 135 20.2 75 
8 4.3 197 18.4 36.3 23 119 15.5 35 
9 4.9 181 16.7 15.9 10 88 13.2 0.1 
10 4.5 166 18.6 59.7         
11 5.2 108 11 23         
12 5.9 195 8.3 33.7         
13 5 200 13.2 35 44 147 20.8 56 
14 4.7 126 14.5 34         
15 4.6 189 12.2 56 37.5 140 19.2 61 
16 6.1 262 16.2 47.1 46 136 24.8 94.5 
17 5.3 230 17.8 80 38.4 148 17.5 45 
18 4.2 200 7.7 72 46.5 150 20 80 
19 5.2 250 16.5 56.2         
20 5.2 168 18.6 103 52 163 20 61.6 
21 3.9 128 16.2 25 39.6 152 17.1 12 
22 5.2 200 13.1 34.6 58 150 25.7 97.3 
23 4 130 7.2 62.2 38.5 150 17 22.5 
24 4.4 208 9.3 189         
25 6.7 265 17.1 57 15.6 94.6 16.8 81 
26 5.2 196 8.1 33 24.5 126 15.4 41 
27 4.2 149 15 45.2 15.4 105 13.9 11 
28 4 128 16 25 43 152 18.6 30 
29 4 197 18.4 35 26.5 117 17.6 78 
30 5.2 200 13.1 34.6 44 145 20.9 88.7 
31 5.6 162 16.5 57.1 40 134 22.2 89 
32 4.5 149 19.8 43.7 8.4 77 14 3 
33 4.3 244 16.9 52 38.5 129 23.1 96 
34 5.7 198 11.1 75.6 25.4 126 16 40 
35 5 281 5.4 220 48.6 132 27.8 94 
36 5.5 189 18.6 54 16.5 102 15.5 55 
37 5.2 199 17.71 53.1 42 161 16.5 9.6 
38 5.9 186 7.6 20.4 10.5 82 15.6 21.5 
39 4.6 183 11.3 54 24 106 21.3 96 
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S.NO S.Ca 8 S.Po4 8 S.ALP 8 
S.Vit D 
8 PTH 8 
U.Ca/Creat 
8 
WEIGHT 
14 
HEIGHT 
14 
1             48 115 
2             37.6 142 
3 9.2 5.8 299 74 43.7 0.03 32 148.2 
4 9 3.3 203 52.9 34.6 0.03 46 151 
5 8.7 2.5 87 42.01 60.8 0.05 83 167 
6 9.5 4.4 67 78 22.2 0.05 37 152 
7 9 4 150 45 35.4 0.05 38.6 137 
8 8.6 4 200 49 20.4 0.12 23.3 120 
9 9.4 4.6 200 81 19.9 0.1 10.6 89 
10                 
11                 
12             23 125 
13 10 4 179 42.7 39.7 0.02 45 146.5 
14                 
15 9 4.1 160 52 46 0.02 37.7 141 
16 8.5 4.6 220 38.2 35 0.03 46.2 136.5 
17 9.2 5.8 187 58 43.7 0.03 38 148.2 
18 9 3.3 203 52 34 0.03 46.8 151 
19                 
20 9 4.6 150 45.3 52 0.03 52 163 
21 9.1 3.9 128 51.2 10.6 0.2 40 153 
22 10 4.9 199 42.8 39.8 0.02 58.4 151 
23 9.5 4.4 112 42 22.2 0.05 38.5 150 
24                 
25 8.6 5 154 45.3 25.3 0.06 15 95 
26 9 4.3 142 52 24.3 0.12 25 127 
27 9.6 5.6 156 61 38.7 0.01 15.6 105 
28 9.1 3.9 113 51 11 0.2 43 152 
29 8.6 4 160 48 21 0.1 27 117 
30 10 4.9 199 42.8 39.7 0.02 45.4 146 
31 9 5 134 49 32 0.03 41 135 
32 9.7 5 154 76 38.7 0.01 8.6 77 
33 9.4 4.4 196 49.3 27 0.02 39 129 
34 9.4 5.5 173 63.4 35.5 0.1 25.2 127 
35 9.2 4.7 240 27.7 102 0.03 49 132 
36 9.2 4.5 199 87 5.7 0.1 16.2 102 
37 9 4.5 198 44.8 32.2 0.07 43 162 
38 9.8 5.8 189 59.3 3.2 0.2 10.5 82 
39 9.5 5.6 260 46.8 31.6 0.04 24 106 
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S.NO BMI 14 
BMI % 
14 S.Ca 14 
S.Po4 
14 
S.ALP 
14 
S.Vit D 
14 PTH 14 
U.Ca/creat 
14 
1 36.3 99.7 8.5 5.3 217 21.12 58.8 0.03 
2 18.65 57.7 9.4 4.7 174 27.94 84 0.01 
3 15 5.74 9.2 5.3 306 59 53.1 0.04 
4 20.2 80.7 9.3 3.7 164 30.67 72.1 0.1 
5 29.76 97.7 9.5 3.5 84 34.4 43 0.16 
6 16 3.1 9.1 3.6 59 43.87 46 0.2 
7 20.5 77.6 8.4 4.2 164 32 30 0.04 
8 15.7 35 9.5 5.4 209 30.27 25.4 0.11 
9 13.3 0.11 9.6 4.6 292 59.5 38.4 0.1 
10                 
11                 
12 14.7 24.7 9.1 5.3 222 52.7 32.8 0.17 
13 21 58 9.5 4.2 227 40.4 33 0.04 
14                 
15 19 61 8.6 4.2 174 27.9 84 0.01 
16 24.8 94.3 8.2 4.7 200 30.3 37.3 0.08 
17 17 45 9 5.3 180 39 53 0.04 
18 20.2 81 9.3 3.7 160 30 72 0.1 
19                 
20 20 61.6 8.6 4.5 158 38.6 57 0.04 
21 17 11.5 8.9 3.6 123 42.7 14.8 0.04 
22 25.6 97.5 9.5 4.2 227 40.4 33.9 0.04 
23 17 22.5 9.1 3.6 159 33.8 46 0.2 
24                 
25 16.1 80.2 8.2 4.5 132 31.6 30.4 0.06 
26 15.5 42.7 9.1 5.3 222 42.7 32 0.1 
27 13.9 11.7 8.6 4.6 142 48.3 46.8 0.03 
28 18.6 30 8.6 3.6 123 43 15 0.04 
29 17.8 79 9.5 5.4 176 30.2 24 0.1 
30 21.1 89.5 9.5 4.2 227 40.4 33.9 0.05 
31 22.5 89 8.6 5.2 174 28.5 46.2 0.03 
32 14 3 9.6 5.4 167 61 22.2 0.01 
33 23.3 96 9.2 4 200 40.2 30.3 0.1 
34 15.6 32 9.6 5.7 185 78 27.9 0.08 
35 27.9 94 9.2 5.2 256 20.8 133 0.01 
36 15.5 55 9.5 5.3 216 74 26.8 0.08 
37 16.3 8.3 9 4.8 179 50 25.4 0.03 
38 15.6 21 9.4 5.6 224 70 2.7 0.2 
39 21.3 96 9.8 5.2 260 43.8 9.9 0.1 
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OBJECTIVES:  
     The objective was to compare effectiveness of three different vitamin D supplementation 
protocols and to establish the effective protocol with minimal side effects for asymptomatic 
vitamin D deficient children.  
 
 
METHODS: 
Children (1-18years) with asymptomatic hypovitaminosis  D (serum 25OHD <20ng/ml) were 
randomized into 3 different oral cholecalciferol supplementation protocols (6000 units 
daily/10,000 units daily/60,000 units weekly once) for  6 weeks. Clinical and biochemical 
(including serum 25OHD, calcium) parameters were monitored at baseline, 2weeks and 8 weeks 
after completing treatment.  The results were analyzed with repeated measures analysis of 
covariance (ANCOVA) using statistical package for social sciences (SPSS) and STATA. 
 
RESULTS: 
 
      Thirty nine children with serum 25OHD <20 ng/ml were randomized into the 3 
cholecalciferol supplementation protocols as above. All the treatment groups showed similar 
improvement in serum 25OHD level 2 weeks after completion of treatment. Children with BMI >  
85th centile showed a lower increase in serum 25OHD level for a particular dose of 
cholecalciferol as compared to children with BMI <85th centile (p=0.02). Hypercalciuria was 
observed during the initial weeks of supplementation in  four participants especially in the group 
receiving the high dose weekly oral cholecalciferol.  Hypercalciuria improved over next couple of 
weeks. 
 
CONCLUSIONS:  
Oral   cholecalciferol 6000 units daily; 10,000 units daily and 60,000 units weekly once; for 6 weeks) showed 
similar efficacy in raising Se 25OHD levels in asymptomatic children with hypovitaminosis D without any 
toxicity.  BMI has a significant influence on the treatment response during the initial phase (i.e.) children with 
BMI >  85th centile require a higher dose of cholecalciferol for a similar rise in Se 25OHD as compared to 
children with BMI <85th centile. 
